CONFERENCE SERIES: Biological Therapeutic Products

Recorded at: 10TH ANNUAL PROTEIN ENGINEERING SUMMIT

Digital Course: PHAGE & YEAST DISPLAY LIBRARIES

 


Order Now 

About this Product: 

This workshop is meant to bring the scientist up to speed on the display technologies covered by the main conference and is tailored for both the novice and those with experience in display technologies.

The workshop will provide an overview of:

  • Phage display and construction of phage-displayed scFv and Fab libraries
  • Yeast display and construction of yeast-displayed scFv and Fab libraries
  • Selection and screening technologies that are compatible with phage and yeast-display libraries
  • Combining phage and yeast display for antibody selection and epitope identification
  • Integrating deep sequencing into the antibody selection pipeline
 

 

 


Product Details:
2 Presentations
113 Slides
1:49:28 Minutes
Digital Download: $345.00
Individual: $345.00
Site License: $1380.00

Formats Available:
Digital Download
 
On Demand 
DVD 

 
 

Agenda at a Glance: 

  • Opening Remarks and Introductions 
  • Making and Using Phage and Yeast Antibody Libraries
    Andrew M. Bradbury, M.B., B.S., Ph.D., Staff Scientist, Biosciences, Los Alamos National Laboratory 
  • Display Technologies for Making Therapeutic Antibodies
    James D. Marks, M.D., Ph.D., Professor, Anesthesia & Pharmaceutical Chemistry, University of California, San Francisco; Chief of Anesthesia and Vice Chairman, Anesthesia & Perioperative Care, San Francisco General Hospital 
  • Q&A with Speakers 
  • End of Short Course 


Speaker Biographies: 


AndrewBradburyAndrew M. Bradbury, M.B., B.S., Ph.D.

Staff Scientist, Biosciences, Los Alamos National Laboratory

Andrew Bradbury was trained in medicine at the universities of Oxford and London, and subsequently practiced medicine for five years (one full time, and four part time) in the UK. He received his Ph.D. (Cambridge University) in the MRC Laboratory of Molecular Biology under the guidance of Dr. Cesar Milstein. After his Ph.D. he spent ten years in Italy: three years as a post doc in the CNR Institute of neurobiology, Rome, Italy; and seven years in Trieste, where he was first visiting professor, and subsequently tenured as assistant professor at the International School for Advanced Studies (SISSA, Trieste, Italy). He has been a technical staff member at Los Alamos National Lab since July 1999. He has worked in the field of phage display and antibody engineering for fifteen years, and has helped organize over thirty international congresses and practical courses in this field, both in Europe and the US. He has published over eighty peer reviewed articles, including a number of reviews and commentaries on phage display and antibody engineering, and has 12 filed patents/invention disclosures. He is one of the founder members of “The Antibody Society”, and is on the editorial board of three journals. Dr. Bradbury's research is funded in part by the New Mexico Spatiotemporal Modeling Center, one of the NIGMS-funded National Centers for Systems Biology

JamesMarksJames D. Marks, M.D., Ph.D.

Professor, Anesthesia & Pharmaceutical Chemistry, University of California, San Francisco; Chief of Anesthesia and Vice Chairman, Anesthesia & Perioperative Care, San Francisco General Hospital

Dr. James D. Marks, Jim, MD, PhD co-founded Hermes Biosciences, Inc. and serves as its Vice President of Antibody Discovery. Dr. Marks serves as the Chief of Anesthesia at San Francisco General Hospital, and also serves as Professor of Anesthesia and Pharmaceutical Chemistry at the University of California, San Francisco (UCSF). Dr. Marks serves as Vice-Chairman of the Department of Anesthesia and Perioperative Care at UCSF. Director of the Medical-Surgical Intensive Care Unit, San Francisco General Hospital. Dr. Marks served as Chairman of Medical Advisory Board at Symphogen A/S. Dr. Marks has been a Member of Scientific Advisory Board at Adimab, LLC since 2007. Dr. Marks serves as a Member of the Scientific Advisory Board at Quinnova Pharmaceuticals, Inc. and Merrimack Pharmaceuticals, Inc. Dr. Marks is a Program Member of UCSF Comprehensive Cancer Center at University of California, San Francisco. Dr. Mark' s research interests include the development of phage display technology for production of human antibodies and the development of techniques for increasing antibody affinity. He serves as Director of HERMES Biosciences, Inc. He serves as Member of Scientific Advisory Board of ImaginAb, Inc. He serves as Director of Silver Creek Pharmaceuticals, Inc. He has published more than 75 scientific papers and acts as a referee for top-ranking international journals including Nature Biotechnology, Nature Medicine, Journal of Molecular Biology, Gene, Blood, and Human Antibodies and Hybridomas. Dr. Marks is the co-inventor on 4 major phage display patents. He holds a Ph.D. from the MRC Laboratory of Molecular Biology, Cambridge, UK on the making of human antibody fragments in bacteria and bacteriophage. He is board certified in Internal Medicine, Anesthesia, and Critical Care Medicine. He was an undergraduate at the University of California Berkeley majoring in biochemistry and received his medical degree from UCSF. He completed residencies in Internal Medicine and Anesthesia as well as a fellowship in Critical Care Medicine, all at UCSF.

About the Conference: 

Cambridge Healthtech Institute’s 10th Annual "PEGS - the essential protein engineering summit" gathered over 1,800 participants in Boston's historic Seaport District for unparalleled breadth of scientific programming and high-caliber speakers in the areas of protein and antibody engineering, including oncology, expression, analytical and safety. This year also featured programs in bioprocessing, biologics for autoimmune diseases, T cell therapy and peptide therapeutics. The continued success of PEGS is driven by the growth in biologics worldwide, the quality of scientific programming presented and valuable networking and collaboration opportunities through open forum discussions.